■这项研究描述了流行病学,临床,北非和中东胃肠道间质瘤(GIST)患者的生存情况。
■这个地区,多中心,观察,回顾性研究收集了11年的人口统计数据,病史,疾病特征,目前GIST的治疗方法,最常见的酪氨酸激酶抑制剂(TKIs)的安全性,第二种癌症,和生存状态。
■分析了201名合格患者的数据:平均年龄为56.9±12.6岁;111名(55.2%)患者为男性,21例(10.4%)患者既往有个人恶性肿瘤。GIST最常见的临床表现是吞咽困难[92例(45.8%)患者]。胃是120例(60.7%)患者中最常见的原发部位,171例(85.1%)患者在诊断时出现局部疾病。198例(98.5%)GISTCD117/CD34阳性。伊马替尼用于新辅助治疗(18/21例),辅助(85/89例),和一线转移治疗(28/33例)设置。与TKIs相关的最常见的非血液学毒性是32/85(37.6%)患者的呕吐。总的来说,100例(49.8%)患者(95CI:42.8-56.7%)存活且无疾病,而30例(14.9%)患者存活且患有活动性疾病。
■我们的AfME人群中GIST的呈现与全球报告一致,更常见的患者>50岁和胃是最常见的主要部位。与通常报道的不同,虽然,我们确实有更多这种疾病的淋巴传播患者。尽管根据分子概况,GIST的治疗存在全球趋势和进展,由于缺乏获得分子谱的途径和较高的相关成本,这在我们的人群中仍远未发生.
UNASSIGNED: This study described the epidemiological, clinical, and survival profiles of patients with gastrointestinal stromal tumor (GIST) in North Africa and the Middle East (AfME).
UNASSIGNED: This regional, multicenter, observational, retrospective study collected 11-year data on demographics, medical history, disease characteristics, current treatment approaches of GIST, the safety of the most common tyrosine kinase inhibitors (TKIs), second cancers, and survival status.
UNASSIGNED: Data of 201 eligible patients were analyzed: mean age was 56.9 ± 12.6 years; 111 (55.2%) patients were men, 21 (10.4%) patients had previous personal malignancy. The most common clinical presentation of GIST was dysphagia [92 (45.8%) patients]. The stomach was the most common primary site in 120 (60.7%) patients, 171 (85.1%) patients had localized disease at diagnosis. 198 (98.5%) GIST cases were CD117/CD34-positive. Imatinib was used in the neoadjuvant (18/21 patients), adjuvant (85/89 patients), and first-line metastatic treatment (28/33 patients) settings. The most common non-hematological toxicity associated with TKIs was vomiting in 32/85 (37.6%) patients. Overall, 100 (49.8%) patients (95%CI: 42.8-56.7%) were alive and disease-free while 30 (14.9%) patients were alive with active disease.
UNASSIGNED: Presentation of GIST in our AfME population is consistent with global reports, being more frequent in patients >50 years old and having the stomach as the most common primary site. Unlike what is usually reported, though, we did have more patients with lymphatic spread of the disease. Despite the global trend and advances in the treatment of GIST according to molecular profile, this is still far to happen in our population given the lack of access to molecular profiles and the high associated cost.